Anders H. Lund

Anders H. Lund

Administrerende Direktør

Scientific focus areas

  • Cancer biology with emphasis on senescence and translational control
  • Non-coding RNA
  • Ribosome biology

 

Education and occupation

  • Director, BRIC, University of Copenhagen, Denmark, 2019 –
  • Director (interim), BRIC, University of Copenhagen, Denmark, 2018 – 2019
  • Professor, BRIC, University of Copenhagen, Denmark, 2009 -
  • Associate professor, BRIC, University of Copenhagen, Denmark, 2004-2009.
  • Post-doc, The Netherlands Cancer Institute, Amsterdam, 1999-2004.
  • Post-doc, Department of Molecular and Structural Biology, University of Aarhus, 1996-1999.
  • PhD., Molecular Biology, University of Aarhus, 1996.
  • Cand. scient., Biology, University of Aarhus, 1993.

 

Honors and Awards

  • Elected to The Royal Danish Academy of Sciences and Letters, 2018

 

Personal stipends

  • Distinguished Investigator, The Novo Nordisk Foundation, 2018-2023.
  • Sapere Aude Topforsker, DFF Advanced Grant, 2015-2019.
  • Hallas-Møller Stipendium, Novo Nordisk Fonden, 2009-2014.
  • Vilhelm Pedersen og Hustrus Seniorforskerstipendium, 2004-2009.
  • Postdoc stipendium (FSS), 1999-2002.

 

Research management

  • Head of independent research laboratory, 2004-
  • Director (interim), Biotech Research and Innovation Centre, University of Copenhagen, 2018-
  • Coordinator, The International Doctoral Programme in Molecular Mechanisms of Disease (iMED), H2020 MSCA COFUND, 2018-2023.
  • Coordinator, The Lundbeck Foundation. “Caught in translation - targeting disease ribosomes” (€1.3M), 2015-2019.
  • Director (founding) of the PhD Career Program (PCAP), Faculty of Health and Medical Sciences, University of Copenhagen 2014-2017.
  • Director of the PhD Graduate Program Molecular Mechanisms of Disease 2011-2017.
  • Scientific Coordinator of the research education program Molecular Mechanisms of Disease 2006 – 2010.
  • Coordinator, ITN Marie Curie EU-FP7 network, ”RNATRAIN”, (€3.5M), 2013-2017.
  • Project coordinator: “Novel medicines for treatment of cancer and neurological disorders”. High technology platform (€6M), the Danish National Advanced Technology Foundation, 2008 - 2012.
  • Board member, Danish Cancer Research Foundation 2011 – 2016
  • Board member, The Scientific Committee of the Danish Cancer Society 2013 - 2018

Scientific Advisory Board, Immagina Biotechnology, 2023 - 

Uddannelse

cand. scient, biologi, Aarhus Universitet, PhD, molekylærbiologi, Aarhus Universitet

ID: 11878